Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study (TIGER)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sophie Gallier, PhD
- Phone Number: +64 7 848 9252
- Email: sophie.gallier@dgc.co.nz
Study Locations
-
-
-
Bangkok, Thailand
- Pediatric Nutrition Research Unit, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- healthy full-term born infants (≥ 37 weeks + 0 days and < 41 weeks + 6 days of gestation)
- birth weight ≥ 2.5 kg and ≤ 4.5 kg
- born from a singleton pregnancy
- live in Bangkok or nearby with no plan for geographical migration before 6 months of age
- for experimental and active comparator groups only: parent(s) has expressed the intention to partially (in combination with breastfeeding) or fully formula-feed the infant and ready to enroll in the study before the age of 4 months/120 days
- for no intervention group only: parent(s) has expressed the intention to predominantly breastfeed (according to study definition) and ready to enroll in the study before the age of 4 months/120 days
- infant has been predominantly breastfed for at least 2 weeks before enrollment
- parent(s) has sufficient Thai language skills to understand the study information, the informed consent, and to comply with the study procedure
- parent(s) is willing and deemed able to fulfil the requirements of the study protocol and procedures
- at least one parent is of legal age of consent
Exclusion Criteria:
- infant has any disorder considered to interfere with nutrition, growth or development of the immune system
- participation of the infant in any other interventional trial or participation of the mother in any intervention trial with infant follow-up
- for experimental and active comparator groups only: infant has been formula-fed for more than 1 week before enrolment
- for experimental and active comparator groups only: cow milk allergy or intolerance of the infant
- for experimental and active comparator groups only: enrolled infant who never consumed any study product until the first visit 2 weeks following enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: infant formula based on whole goat milk
|
Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
|
|
Active Comparator: Infant formula based on cow milk proteins
|
Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
|
|
No Intervention: Predominantly breastmilk
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in daily frequency of regurgitation during the transition period from breastfeeding to formula feeding
Time Frame: From Day 0 to Day 28
|
Parental diary record of number of regurgitation per day reviewed at Day 0, Day 14 and Day 28
|
From Day 0 to Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of infant regurgitation
Time Frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
Rome IV criteria diagnosed by physician
|
Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
|
Frequency of infant colic
Time Frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
Rome IV criteria diagnosed by physician
|
Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
|
Frequency of functional constipation
Time Frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
Rome IV criteria diagnosed by physician
|
Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
|
Stool consistency
Time Frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
Stool consistency based on Brussels infants and toddler stool scale (BITSS)
|
Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
|
Stool frequency
Time Frame: Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
Number of defecations per day
|
Day 0, Day 14, Day 28, and Age 8, 12, 16, 20 and 24 weeks
|
|
Feeding difficulties
Time Frame: Day 0, Day 14, Day 28, and Age 8, 16 and 24 weeks
|
NeoEAT questionnaire
|
Day 0, Day 14, Day 28, and Age 8, 16 and 24 weeks
|
|
Sleep
Time Frame: Day 0, Day 28, and Age 12 and 24 weeks
|
Brief Infant Sleep questionnaire
|
Day 0, Day 28, and Age 12 and 24 weeks
|
|
Biochemical and metabolic markers: saliva markers
Time Frame: Day 0 and Day 14
|
Saliva: inflammation markers (including enzymes reported in U/mL)
|
Day 0 and Day 14
|
|
Biochemical and metabolic markers: saliva markers
Time Frame: Day 0 and Day 14
|
Saliva: stress markers (including hormones reported in ng/mL)
|
Day 0 and Day 14
|
|
Biochemical and metabolic markers: saliva markers
Time Frame: Day 0 and Day 14
|
Saliva: inflammation markers (including proteins reported in µg/mL)
|
Day 0 and Day 14
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sirinuch Chomtho, MD, PhD, Chulalongkorn University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Signs and Symptoms, Digestive
- Infant, Newborn, Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Laryngeal Diseases
- Gastroesophageal Reflux
- Gastrointestinal Diseases
- Digestive System Diseases
- Constipation
- Colic
- Laryngopharyngeal Reflux
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Caseins
Other Study ID Numbers
Other Study ID Numbers
- DGC202106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.